DGI-062 Sorafenib, Sunitinib and Everolimus in Metastatic Renal Cell Carcinoma: Efficacy and Safety: Abstract DGI-061 Table 1
نویسندگان
چکیده
منابع مشابه
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
PURPOSE Sunitinib and sorafenib are novel tyrosine kinase inhibitors (TKIs) that have shown significant clinical activity in metastatic clear cell renal cell carcinoma (RCC). The activity of sunitinib and sorafenib in non-clear cell histologies has not been evaluated. PATIENTS AND METHODS Clinical features at study entry and treatment outcomes were evaluated in patients with metastatic papill...
متن کاملSunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.
BACKGROUND Although clinical trials with sunitinib and sorafenib in metastatic renal cell carcinoma (mRCC) have included patients with moderate renal insufficiency (RI), the incidence of renal toxicity induced by their administration as well as the safety of these agents in patients with more severe renal insufficiency has not been extensively reported. PATIENTS AND METHODS Patients with mRCC...
متن کاملLong-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.
BACKGROUND Metastatic renal cell carcinoma (mRCC) patients receiving first-line sunitinib typically survive >2 yr, with chronic treatment sometimes extending to ≥6 yr. OBJECTIVE To analyze long-term safety with sunitinib in mRCC patients. DESIGN, SETTING, AND PARTICIPANTS Data were pooled from 5739 patients in nine trials, comprising seven phase II studies, a phase III study, and an expande...
متن کاملEfficacy and Safety of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma
Objective: This study aim to assess the efficacy and safety of sunitinib in Japanese patients with metastatic renal cell carcinoma (mRCC) in general clinical practice. Patients and Methods: Non-selected fifty eight Japanese patients with mRCC were treated with sunitinib. Overall survival (OS) and time to treatment failure (TTF) were estimated. Response rate and safety profiles were also assesse...
متن کاملEfficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience
PURPOSE We assessed the efficacy and safety of the tyrosine kinase inhibitor sunitinib in Korean patients with metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS Between September 2007 and December 2009, all twenty-one patients who had mRCC with a clear-cell component were retrospectively reviewed. Sunitinib was administered orally at a dose of 50 mg daily until disease progression...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Hospital Pharmacy
سال: 2013
ISSN: 2047-9956,2047-9964
DOI: 10.1136/ejhpharm-2013-000276.328